(S) -VQW-765
(S) -VQW-765 ((S) -AQW-051) is an orally active, selective and effective α7 nicotinic ACh receptor (nAChR) partial agonist. (S) -VQW-765 has potential applications in cognitive disorders related to neurological diseases, such as Alzheimer's disease or schizophrenia[1][2].
Product Specifications
Product Name Alternative
(S) -AQW-051
UNSPSC
12352005
Target
NAChR
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel; Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/s-vqw-765.html
Purity
98.00
Solubility
10 mM in DMSO
Smiles
CC(C=C1)=CC=C1C2=NC=C(C=C2)O[C@H]3C4CCN(CC4)C3
Molecular Formula
C19H22N2O
Molecular Weight
294.39
References & Citations
[1]Feuerbach D, et al. AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation. Br J Pharmacol. 2015 Mar;172 (5) :1292-304. |[2]Mazurov A, et al. Nicotinic acetylcholine receptor modulators[J]. Small Molecule Therapeutics for Schizophrenia, 2015: 213-253.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GTR15297025 1 Vial
Lentiviral human MECP2 shRNA (UAS) - Lentiviral human MECP2 shRNA (UAS, GFP) plasmid
Ask
View Details 